Tadalafil Tablet
Product Images NDC 43547-049

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 43547-049). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Solco Healthcare Us, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

F35596a7-figure-01 (F35596a7 Figure 01)

Chemical structure diagram of the active ingredient tadalafil, showing its molecular framework with ring structures and functional groups typical of this compound.*

FDA Label Image

F35596a7-figure-02 (F35596a7 Figure 02)

A set of four line graphs showing differences in blood pressure between tadalafil and placebo over time in hours. The graphs depict standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure changes with error bars representing variability.*

FDA Label Image

F35596a7-figure-03 (F35596a7 Figure 03)

Two line graphs showing the effect on systolic blood pressure over 24 hours. The top graph depicts standing systolic blood pressure changes post-dose, comparing Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg. The bottom graph shows supine systolic blood pressure changes over the same time period with the same comparisons. Both graphs have time post-dose (hours) on the x-axis and change in systolic blood pressure (mmHg) on the y-axis.*

FDA Label Image

F35596a7-figure-04 (F35596a7 Figure 04)

A line graph showing changes in systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo with doxazosin. Four lines represent different treatments: 20 mg tadalafil at 08:00 with 8 mg doxazosin, placebo at 08:00 with 8 mg doxazosin, 20 mg tadalafil at 20:00 with 8 mg doxazosin, and placebo at 20:00 with 8 mg doxazosin.*

FDA Label Image

F35596a7-figure-05 (F35596a7 Figure 05)

A line graph depicting plasma tadalafil concentration (µg/L) over time (hours) for different doses: single 20 mg dose, single 5 mg dose, and once-daily 5 mg dosing for five consecutive days. The graph shows concentration curves with error bars across a time span of 0 to 120 hours, highlighting pharmacokinetic profiles for each dosing regimen.*

FDA Label Image

F35596a7-figure-06 (F35596a7 Figure 06)

A line graph depicting change from baseline in IPSS total score over 12 weeks of treatment comparing tadalafil tablets 5 mg and placebo. The x-axis shows treatment duration in weeks, and the y-axis shows change in IPSS score. The tadalafil group shows a greater decrease in score compared to placebo, with statistical significance indicated at 12 weeks.*

FDA Label Image

F35596a7-figure-07 (F35596a7 Figure 07)

A line graph showing change from baseline in IPSS total score over a 12-week treatment period comparing Tadalafil 5 mg tablets and placebo. The graph displays greater score reduction with Tadalafil compared to placebo, with statistical significance indicated at week 4 and week 12 (p<0.01). The x-axis represents duration of treatment in weeks and the y-axis the change from baseline in IPSS total score.*

FDA Label Image

F35596a7-figure-08 (F35596a7 Figure 08)

A line graph illustrating the least-squares mean change from baseline over 26 weeks of therapy comparing Tadalafil/Finasteride versus Placebo/Finasteride. The horizontal axis represents weeks of therapy (0, 4, 12, 26), and the vertical axis shows LS mean change from baseline. Two lines plot changes for each treatment group, with annotations for statistical significance (p values).*

FDA Label Image

F35596a7-figure-09 (F35596a7 Figure 09)

A line graph comparing change from baseline in IPSS Total Score over 12 weeks treatment duration for Tadalafil tablets 5 mg and placebo. The vertical axis shows score changes, with Tadalafil showing greater reduction over time compared to placebo. The horizontal axis represents weeks of treatment. Statistical significance (p<0.01) is noted at 12 weeks.*

FDA Label Image

2.5 mg 30 Ct (F35596a7 Figure 10)

Tadalafil Tablets, USP 2.5 mg oral tablets label by Solco Healthcare US, LLC. The label states tablets should not be split and the entire dose should be taken. The package contains 30 tablets. Manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd., China. Storage and safety warnings are included, along with a barcode and website link for patient information.*

FDA Label Image

5 mg 30 Ct (F35596a7 Figure 11)

The label for Tadalafil Tablets, USP, 5 mg strength, distributed by Solco Healthcare US, LLC. The label shows a blue design with dosage instructions stating tablets should not be split and the entire dose should be taken. The package contains 30 tablets. The label includes storage instructions and manufacturer details (Zhejiang Huahai Pharmaceutical Co., Ltd., China).*

FDA Label Image

10 mg 30 Ct (F35596a7 Figure 12)

Tadalafil Tablets USP 10 mg oral tablets label, packaging 30 tablets. The label includes dosage instructions referencing accompanying literature, storage conditions, warnings to keep out of reach of children, and manufacturer Zhejiang Huahai Pharmaceutical Co., Ltd. The product is distributed by Solco Healthcare US, LLC. The label also shows the NDC 43547-050-03 and contains website and barcode details.*

FDA Label Image

20 mg30 Ct (F35596a7 Figure 13)

Label for Tadalafil Tablets, USP 20 mg oral tablets by Solco Healthcare US, LLC. The label states the product contains 30 tablets, is prescription only, and provides storage instructions and manufacturer information for Zhejiang Huahai Pharmaceutical Co., Ltd., China. The label warns tablets should not be split and the entire dose taken.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.